From The Market Herald
Interim results from a Race Oncology (RAC) preclinical research program show its Zantrene drug has the potential to enhance immunotherapy outcomes in melanomaRace says the research program has found that used at low concentrations, Zantrene enhances cancer immunotherapy in mice in three distinct and complementary waysThis includes the direct killing of melanoma cells, the activation of immune cells and the reduction of the expression of immune evasion genes in the tumourRace says these results will support further clinical research using Zantrene with immune therapy treatments to improve melanoma patient outcomesRace shares are up 9.01 per cent to $1.82 at 11:03 am AESTRace shares were up 9.01 per cent to $1.82 at 11:03 am AEST.
From The Market HeraldInterim results from a Race Oncology (RAC)...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |